Accelerated Approval: US FDA Should Explain Why An Ongoing Trial Is Not Required
Executive Summary
Having a confirmatory trial underway at the time of approval should be the ‘default expectation’ and the agency should publicly explain when and why it grants exceptions to this rule, experts said at a National Academies meeting on accelerated approval.
You may also be interested in...
FDA, CMS And Accelerated Approval: Flipping The Script
The US Medicare agency’s restrictive coverage policy for Alzheimer’s antibodies is a clear threat to the FDA accelerated approval pathway. Now the payor is going to try a different approach to strengthen the pathway.
Real-World Evidence For Accelerated Approval: NASEM Is A Tough Crowd
Biopharma companies continue to hold out hopes that Real-World Evidence can help expand use of the US FDA accelerated approval pathway by making confirmatory studies more viable. A recent National Academies of Science, Engineering and Medicine workshop suggests there is a long way to go in building a broader consensus behind the approach.
US FDA Urged To Improve Messaging To Professional Societies On Accelerated Approval Withdrawals
Lengthy withdrawal process creates an opening for the FDA to better convey its concerns about a medicine’s benefit-risk profile in a way that impacts prescribing guidelines, Johns Hopkins’ Joshua Sharfstein says; CDER’s Jacqueline Corrigan-Curay says new expedited withdrawal procedures under omnibus law appear more ‘streamlined’ than those followed for Makena.